Stockreport

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers [Yahoo! Finance]

Sonnet BioTherapeutics Holdings, Inc.  (SONN) 
PDF immunotherapeutic drugs for cancer, announced today the publication of clinical data on SON-1010 in Frontiers in Immunology . SON-1010, Sonnet's lead proprietary monofun [Read more]